Investec Reconfirms GBX 735.00 Price Objective On Tate Lyle PLC (LON:TATE), Reconfirms “Buy” Rating; Shorts at Aclaris Therapeutics (ACRS) Lowered By 7.67%

In a report published on Monday, 29 January, Tate Lyle PLC (LON:TATE) stock “Buy” was restate at Investec. They currently have a GBX 735.00 PT on the stock. Investec’s PT suggests a potential upside of 13.69% from the company’s current price.

Aclaris Therapeutics Incorporated (NASDAQ:ACRS) had a decrease of 7.67% in short interest. ACRS’s SI was 2.78M shares in January as released by FINRA. Its down 7.67% from 3.01M shares previously. With 296,400 avg volume, 9 days are for Aclaris Therapeutics Incorporated (NASDAQ:ACRS)’s short sellers to cover ACRS’s short positions. The SI to Aclaris Therapeutics Incorporated’s float is 14.28%. The stock decreased 0.33% or $0.08 during the last trading session, reaching $24.53. About 278,089 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has risen 25.57% since January 29, 2017 and is uptrending. It has outperformed by 8.87% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. Leerink Swann initiated Aclaris Therapeutics, Inc. (NASDAQ:ACRS) on Tuesday, November 29 with “Outperform” rating. The company was initiated on Friday, September 30 by JMP Securities. As per Monday, September 19, the company rating was maintained by Jefferies. Cantor Fitzgerald maintained it with “Buy” rating and $5000 target in Wednesday, August 9 report. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Friday, July 28 by Jefferies. The rating was maintained by Jefferies with “Buy” on Friday, August 12. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has “Buy” rating given on Friday, June 10 by Guggenheim. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Thursday, August 31. On Tuesday, November 7 the stock rating was maintained by Cantor Fitzgerald with “Buy”. As per Monday, November 2, the company rating was initiated by Jefferies.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $756.38 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

The stock decreased 0.06% or GBX 0.4 during the last trading session, reaching GBX 645.8. About 172,402 shares traded. Tate & Lyle plc (LON:TATE) has 0.00% since January 29, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 18 analysts covering Tate Lyle PLC (LON:TATE), 6 have Buy rating, 1 Sell and 11 Hold. Therefore 33% are positive. Tate Lyle PLC has GBX 900 highest and GBX 505 lowest target. GBX 748.56’s average target is 15.91% above currents GBX 645.8 stock price. Tate Lyle PLC had 201 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, May 26 by Shore Capital. Jefferies upgraded Tate & Lyle plc (LON:TATE) on Monday, October 23 to “Buy” rating. The firm has “Buy” rating by Jefferies given on Friday, December 4. The firm has “Buy” rating by Deutsche Bank given on Thursday, July 30. The firm earned “Hold” rating on Friday, November 13 by Numis Securities. Deutsche Bank maintained Tate & Lyle plc (LON:TATE) on Monday, November 7 with “Buy” rating. The company was maintained on Friday, November 6 by BNP Paribas. The firm earned “Neutral” rating on Friday, November 6 by JP Morgan. The stock of Tate & Lyle plc (LON:TATE) earned “Buy” rating by Liberum Capital on Thursday, October 15. The firm earned “Buy” rating on Monday, January 18 by Deutsche Bank.